BSE See NSE See 52,323.33
-178.65 (-0.34%)

Aurobindo Pharma receives US regulatory nod for Acetaminophen injection

Anthony Fernandes
/ Categories: Mindshare, DSIJ News
Rate this article:
Aurobindo Pharma receives US regulatory nod for Acetaminophen injection

On Thursday, Aurobindo Pharma informed that it has received final approval from US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen injection, 1,000 mg/ 100 ml single-dose vial (SDV), which is a generic equivalent of Mallinckrodt’s Ofirmev injection.

The product, which is expected to be launched in December 2020, is indicated for the treatment of mild to moderate pain in adult and pediatric patients of 2 years and older. The injection is also set to treat moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients of 2 years and above along with the reduction of fever in adult & pediatric patients.

According to data from IMS Health, the approved product has an estimated market size of US$ 339 million for the twelve-month ending August 2020. This is the 75th ANDA to be approved out of Unit IV formulation facility in Hyderabad (India), used for manufacturing injectable & ophthalmic products.

The company’s US business is poised to grow in double digits in the quarters ahead due to a combination of factors including studying a new product line, opportunities arising out of shortage of products in the US, and an expected recovery in the injectable business. The latest approval for Acetaminophen injection in the US markets is likely to aid in the revenue growth for the company in the US markets.

On Thursday, the stock of Aurobindo Pharma closed at Rs 782.45 per share, down by 2.84 per cent or Rs 22.85 per share on BSE, against a 0.37 per cent decline in the benchmark index. Its 52-week high is recorded at Rs 967.60 and the 52-week low is Rs 281.15 on BSE.

Previous Article Ashok Leyland rises 5 per cent on launch of BOSS LX & LE with i-Gen6 technology
Next Article L&T strong order inflow may boost sentiment and break range-bound trend
Please login or register to post comments.

Get A Call From Industry Experts

Send Otp

   I authorize DSIJ Pvt Ltd to contact me. This will override registry on the NDNC.


High Beta Low Price stock: Nectar Life soared more than 51 per cent in one month

On Thursday when frontline indices cracked along with the broader markets, Nectar Lifescience Ltd (NLL) gained more than 7 per cent in the last closing hour of the session.

Yogesh Supekar / Article rating: 4.7
The stock has more than doubled in three months and is up by more than 81 per cent in one year. In past one month alone the stock has gained by...